AMIX

Long-term Pain Relief Results: A post hoc analysis of a study on patients with severe pancreatic cancer pain showed a nearly 66% reduction in pain, with a mean decrease of 5.08 on the VAS pain scale, and 100% of responders were opioid-free at the 3-month follow-up.

Quality of Life Improvements: Responding patients reported significant enhancements in quality of life, including better sleep quality, increased energy levels, and improved ability to engage in daily activities, alongside reduced symptoms like tension and vomiting.

Expansion of Clinical Trials: Following positive results from the initial proof-of-concept study, Autonomix Medical is expanding its research to include additional visceral cancers and earlier-stage pancreatic cancer patients, aiming to address a broader market for pain management.

Innovative Technology Development: Autonomix is focused on advancing a catheter-based microchip sensing array technology for diagnosing and treating diseases involving the nervous system, with initial applications targeting pain management in pancreatic cancer.

Patent Announcement: Autonomix Medical, Inc. has been granted a new patent (No. 3,697,298) by the European Patent Office for its technology that captures and processes physiological signals in real-time.

Market Potential: The company holds a total of 80 issued patents and 40 pending applications, positioning itself to capitalize on multi-billion-dollar market opportunities in cardiovascular, renal, and other high-burden diseases.

Innovative Technology: Autonomix's technology includes a catheter-based microchip sensing array that enhances the detection of neural signals, aiming to revolutionize diagnosis and treatment for various conditions, including chronic pain and hypertension.

Future Development: The company is initially focusing on treating pancreatic cancer-related pain with its investigational technology, which has not yet received marketing clearance in the U.S.

Webinar Announcement: Autonomix Medical, Inc. will host a virtual investor webinar on August 21, 2025, at 1:00 PM ET, featuring CEO Brad Hauser and moderated by Jeffrey S. Cohen from Ladenburg Thalmann.

Participation Details: Attendees can pre-submit questions via email and register for the event through the company's website or directly via a provided link.

Company Overview: Autonomix focuses on innovative medical technologies for diagnosing and treating nervous system diseases, utilizing a catheter-based microchip sensing array for enhanced neural signal detection.

Initial Focus: The company is initially targeting pain management solutions, particularly for pancreatic cancer, with plans to expand its technology to various medical indications across different fields.